New drug combo shows promise in Hard-to-Treat cancers

NCT ID NCT04303858

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called eciskafusp alfa, alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was terminated early, but results help guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Clinica Universitaria de Navarra

Pamplona, Navarre, 31008, Spain
Cliniques Universitaires St-Luc

Brussels, 1200, Belgium
Erasmus MC

Rotterdam, 3015 GD, Netherlands
Herlev Hospital

Herlev, 2730, Denmark
Hospital Clinic Barcelona

Barcelona, 08036, Spain
Hospital del Mar

Barcelona, 08003, Spain
NKI/AvL

Amsterdam, 1066 CX, Netherlands
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie

Warsaw, 02-781, Poland
Rigshospitalet

København Ø, 2100, Denmark
UZ Leuven Gasthuisberg

Leuven, 3000, Belgium
Uniwersyteckie Centrum Kliniczne

Gdansk, 80-214, Poland
Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.